Drug Profile
Research programme: anti-CD40L and anti-CD40 agents - Bristol-Myers Squibb
Alternative Names: Anti-5c8 - Bristol-Myers Squibb; Anti-CD40L antibody - BMS; Anti-gp39 - Bristol-Myers Squibb; Anti-gp39 monoclonal antibody - Bristol-Myers Squibb; Anti-gp39 monoclonal antibody MR1; Anti-T-BAM - Bristol-Myers Squibb; Anti-TRAP - Bristol-Myers Squibb; BMS-202448; MR1Latest Information Update: 10 Aug 2021
Price :
$50
*
At a glance
- Originator Bristol-Myers Squibb
- Class Monoclonal antibodies
- Mechanism of Action CD40 antigen inhibitors; CD40 ligand inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Immunological disorders
Most Recent Events
- 10 Aug 2021 Preclinical development is ongoing in Immunological-disorders in USA (Parenteral) (Bristol-Myers Squibb pipeline, August 2021)
- 10 Aug 2021 Phase-I clinical trials in Immunological disorders in USA (Parenteral) (Bristol-Myers Squibb pipeline, August 2021)
- 10 Aug 2021 Phase-I clinical trials in Immunological disorders in USA (unspecified route) (Bristol-Myers Squibb pipeline, August 2021)